State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy?
|
|
- Bridget Hamilton
- 6 years ago
- Views:
Transcription
1 ESMO Preceptorship Programme NSCLC Singapore dec 2016 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo Adjuvant chemotherapy? Pr Jaafar BENNOUNA Université de Nantes France Institut de Cancérologie de l Ouest Nantes
2 COI Disclosure Advisory Boards and Symposium presentations Astra-Zeneca Boehringer-Ingelheim Lilly Roche BMS
3 The MRC 1995 meta analysisfor the beginningof the story 14 randomized trials : 4357 patients 1st group : alkylating agents containing regimen riskof death: + 15 % survival: -5 % at5 y. 2cnd group : UFT based chemo. non conclusive results decreasein the riskof death 3rd group : cisplatin based chemo. Non-smallCellLung Cancer Collaborative Group -BMJ 1995
4 MRC 1995 meta analysis (3rd group : CDDP based chemo.) 8 randomizedphase III trials pts Surgery vs surgery + cisplatin-based chemo. Absolutebenefitfromchemo. of 5 % at5 years Not statistically significant: HR: 0.87 [95% CI: ] (p=0.08) These findings prompted renewed interest of postoperative chemotherapy in completely resected NSCLC. Only trials with cisplatin-based chemotherapy Non-smallCellLung Cancer Collaborative Group -BMJ 1995
5 meta analysis 11 randomized trials : 5716 patients 6 randomized trials : 2003 patients In these trials, adjuvant chemotherapy yielded a survival advantage over surgery alone(hr 0.872). In a subset analysis, both cisplatin-based chemo. (HR, 0.891) and single-agent therapy with UFT (HR 0.799) were found to yield a significant survival benefit. UFT single agent-based adjuvant chemotherapy in Japan. Mostlyearlystages(T1,T2,N0)andadenocarcinoma84% HR0.74( ) Hotta K, et al. J Clin Oncol2004 ; Hamada C, et al. J Clin Oncol2005
6 2010 : Adjuvant chemo., with or without postoperative radiotherapy, in operable NSCLC: two meta analyses of individual patient data 1 st meta-analysis:surgery+ctversussurgery 34trials:8447patients absolute increase in survival of 4% at 5 y. (from 60%to64%) HR0.86( ) 2cnd meta-analysis: surgery + RT-CT versus surgery + RT 13trials:2660patients absolute increase in survival of 4% at 5 y. (from 29%to33%). HR0.88( ) NSCLC Meta-analyses Collaborative Group. Lancet 2010
7 Effect of adjuvant treatment according to the type of chemotherapy NSCLC Meta-analyses Collaborative Group. Lancet 2010
8 7 major adjuvant studiesin NSCLC study n stage chemotherapy comments CALGB IB paclitaxel + carboplatin vs obs No Survival benefit with paclitaxel + carboplatin for stage IB Kato H 999 I UFT vs obs Survival benefit for stage IB only (T2N0) IALT 1867 I IIIA platin-based Chemo. vs obs Survival benefit at 5 y. Not maintained > 5 y. increase in noncancer deaths in the CT arm. ALPI 1209 I IIIA MVP vsobs No survival benefit of CT at 5 years BLT 381 I IIIA platin-based chemo. vs obs No survival benefit with adjuvant CT ANITA 798 I IIIA vinorelbine+ cisplatinvsobs Survival benefit of CT at 5 and 7 y for stage II and IIIA JBR IB- II vinorelbine + cisplatin vs obs Significant survival benefit at 5 years for stage II Benefit maintained after 9 years. * TNM V and VI classification Strauss G M et al. J Clin Oncol 2008 ; Kato H, et al. N Engl J Med 2004 ; Arriagada R, et al. N Engl J Med 2004 ; Scagliotti GV, et al. J Natl CancerInst2003;WallerD,etal.EurJCardiThoacSurg2004;WintonT,etal.NEnglJMed2005;DouillardJY,etal.LancetOncol2006
9 IALT : randomizedphase III study(n=1,867) Stage I (36 %) ; II (24 %) ; IIIA (40 %) Pneumonectomy (35 %) ; squamous histology(46 %) ; adjuvant radiotherapy(31 %) ArriagadaR, et al. N EnglJ Med 2004 ArriagadaR, et al. J Clin Oncol2010
10 IALT : randomizedphase III study(n=1,867) Significantbenefitof cisplatin-basedct at5 y. HR 0.86 (p=0.03) ; +4.1 % at5 years, An updatedanalysiswaslaterpublishedat7.5 y. HR 0.91 ; p= ArriagadaR, et al. N EnglJ Med 2004 ArriagadaR, et al. J Clin Oncol2010 An excess of non-cancer related deaths was noticed in the chemotherapy arm with time Long FU isneededto reallyevaluatethe benefitof ajuvantct
11 IALT : randomizedphase III study(n=1,867) According to the author, all test for interaction are negative, not allowing p values among groups A different analysis on stage published by Strauss et al showed a significant p value for stage III only (p=0.035) (Hematol Oncol ClinNAm , ) The study was initially calculated on 3000 pts and therefore lacks power for subgroup analysis ArriagadaR, et al. N EnglJ Med 2004 ArriagadaR, et al. J Clin Oncol2010
12 CALGB 9633 : A randomized phase III study (n=344) Stage IB only; Lobectomy (89 %) ; squamoushistology(39 %) Compliance(paclitaxel+ carboplatinarm) : 4 cycles (85 %) ; 55 % (full dose) Overall population Tumor 4 cm Adjuvant chemotherapyisnot the standard of care for all patients withstage IB NSCLC Strauss G M et al. JCO 2008
13 JBR10 : A randomized phase III study (n=482) Stage IB (45 %) ; IIA (15 %) ; IIB (40 %) ; pneumonectomy(23 %) Chemoarm : vinorelbineweekly25 mg/m² + cisplatin50 mg/m² d1,d8 (4 cycles d1,d28) The medianfollow-up was9.3 yearswitha confirmedbenefit, stillconfinedto stage II For stage IB and size 4 cm ; HR 0.66 ( ) Overall survival: stage II Overall survival: stage IB WintonT, et al. N EnglJ Med 2005 ; ButtsCA, et al. J Clin Oncol2010
14 ANITA trial : A randomized phase III study (n=840) Stage IB (35 %) ; II (30 %) ; IIIA (35 %) ; lobectomy(58 %) ; Squamoushistology(59 %) Chemo arm: vinorelbine weekly 30 mg/m² + cisplatin 100 mg/m² d1(4 cycles d1,d28) Compliance: Median% planneddose: CDDP 76%, VNR 56% OBS. NVB + CDDP mos P- value HR 0.80 [ ] % benefitin OS 1 years years years years +8.4 Douillard JY et al. Lancet Oncol. 2006
15 ANITA trial : survival according to lymph nodes status N0 status N1 status N2 status OBS. CT OBS. CT OBS. CT mos mos mos Douillard JY et al. Lancet Oncol. 2006
16 ANITA trial : Conclusion Significant improvement in survival with adjuvant vinorelbine/cisplatin StageIB:nodifferenceat5-years StageII:+12.6%at5-years StageIIIA:+16.4%at5-years The effect of vinorelbine/cisplatin is demonstrated in stage II and IIIAbutnotinIB Douillard JY et al. Lancet Oncol. 2006
17 LACE meta analysis LACE meta analysis LACE vinorelbine meta analysis Population Patients with completely resected NSCLC Inclusion criteria Included studies Patients characteristics Main objective CDDP-based vs Obs CDDP-based + PORT vs PORT 5 studies included ALPI, BLT, IALT, JBR10, ANITA n= 4,584 IA: 8%, IB: 30%, II: 35%, III: 27% Overall Survival of CDDP-based regimens NVB + CDDP vs Obs NVB + CDDP + PORT vs PORT 4 studies included BLT, IALT, JBR10, ANITA n= 1,888 IA: 2%, IB: 34%, II: 38%, III: 26% OverallSurvivalof VNR + CDDP regimens PORT= post-operativert Pignon JP, et al. JCO 2008; Douillard JY, et al., JTO 2010
18 LACE meta analysis 5 trials Absolute survival benefit of 5.3% at 5-years 4 trials Absolute survival benefit of 8.9% at 5-years LACE LACE NAVELBINE Pignon JP, et al. JCO 2008; Douillard JY, et al., JTO 2010
19 LACE meta analysis : according to trials LACE LACE NAVELBINE Pignon JP, et al. JCO 2008; Douillard JY, et al., JTO 2010
20 LACE meta analysis : according to TNM stage LACE LACE NAVELBINE Detrimental effect for stage I Pignon JP, et al. JCO 2008; Douillard JY, et al., JTO 2010
21 Vinorelbine + cisplatin in adjuvant setting Vinorelbine plus cislatin improve overall and disease-free survivals of patients with resected NSCLC Vinorelbine 30 mg/m² associated with cisplatin 320 to 400 mg/m² are the recommended doses What about the other cisplatin-doublets?
22 E1505 Chemotherapy Subset Analysis in Early Stage, Resected NSCLC E1505: randomized phase III study evaluated bevacizumab plus cisplatin-based doublet chemotherapy in early stage resected NSCLC(n=1501) Cisplatin partners: vinorelbine (n=377), docetaxel (n=343), gemcitabine (n=283), pemetrexed(n=497) Bevacizumab addition failed to improve OS (HR: 0.99; 95% CI: ; P =.90) or DFS(HR:0.99;95%CI: ;P=.95) [3] Trial stopped early for futility Wakelee HA, et al. ASCO Abstract 8507.
23 E1505 Chemotherapy Subset Analysis in Early Stage, Resected NSCLC OS not significantly different between chemotherapy groups Wakelee HA, et al. ASCO Abstract 8507.
24 Squamous (n = 422) Nonsquamous (n = 1078) E1505 AEs Grade 3 AEs, % V (n = 127) D (n = 140) G (n = 149) V (n = 241) D (n = 199) G (n = 132) Anemia Febrile neutropenia Neutropenia Thrombocytopeni a Fatigue P (n = 485) Diarrhea Nausea Vomiting Dehydration Hypertension Thromboembolis m Wakelee HA, et al. ASCO Abstract WORST DEGREE
25 E1505 Chemotherapy Subset Analysis: Conclusions OS and DFS by chemotherapy subset in pts receiving adjuvant cisplatinbased chemotherapy for early stage resected NSCLC are similar Toxicity profiles of chemotherapy agents similar to known profiles Neutropenia/febrile neutropenia occurred more frequently with vinorelbine and thrombocytopenia occurred more frequently with gemcitabine Grade 3 toxicity lower in pemetrexed (nonsquamous) group than in other chemotherapy groups(p <.001) Wakelee HA, et al. ASCO Abstract 8507.
26 «Adjuvant chemotherapy should be offered to patients with resected stage II and III [I,A] and can be considered in patients with resected stage IB disease and a primary tumor > 4cm[II,B]. Pre-existing comorbidities, time from surgery and post-operative recovery need to be taken into account in this decision in a multidisciplinary tumor board[v,a]. For adjuvant chemotherapy, a two-drug combination with cisplatin is preferable [I,A]. In randomised studies, the attempted cumulative cisplatin dose was up to 300mg/m², delivered in 3 to 4 cycles. The most frequently studied regimen is cisplatin-vinorelbine. In the current stage of knowledge, the choice of adjuvant chemotherapy should not be guided by molecular analysis such as, e.g. ERCC-1 or mutation testing[iv,b]»
27 Is there a place for neo adjuvant chemotherapy? n Stage Phase III Overall Survival DepierreA, et al J Clin Oncol I, II, IIIA pre-op CT vs surgery no difference except for stage I,II Gilligan D, et al (MRC) Lancet 2007 PistersKM, et al (SWOG 9900) J Clin Oncol I,II,III pre-op CT vs surgery no difference 354 IB, II, IIIA pre-op CT vs surgery no difference Scagliotti GV, et al (2012) J Clin Oncol IB, II, IIIA pre-op CT vs surgery no difference except for stage IIB, IIIA WesteelV, et al (IFCT 0002) EurJ Cancer I, II pre-op CT vs peri-op CT no difference FelipE, et al (NATCH) J Clin Oncol IA (>2cm), II, T3N1 pre-op CT vs post-op CT vs surgery no difference
28 The NATCH trial Pre operative chemo. vs surgery Adjuvant chemo. vs surgery In this trial, in which the treatment decision was made before surgery, more patients were able to receive preoperative than adjuvant treatment. FelipE, et al. J Clin Oncol2010
29 Meta analysis: pre operative chemotherapy versus surgery alone Pre operative chemotherapy versus surgery alone 2,200 patients 10 studies ScagliottiGV, et al. J Clin Oncol2011
30 Pre operative chemotherapy for NSCLC Meta analysis of individual participant data Stage IB to IIIA 15 randomized controlled trials 2,385 patients HR 0.87 ( ) BurdettS, et al. Lancet 2014
31 Pre operative chemotherapy for NSCLC Meta analysis of individual participant data The absolutesurvivalimprovementat5 yearswas5 %(40% to 45 %) BurdettS, et al. Lancet 2014
32 Pre operative chemotherapy for NSCLC Meta analysis of individual participant data Forest plot of the interactions between the effect of preoperative chemotherapy on survival and covariates Noevidenceofadifferenceintheeffect on survival by chemotherapy regimen number of drugs platinum agent used age sex performance status histology clinical stage BurdettS, et al. Lancet 2014
33 In view of the equivalence of neo-adjuvant and adjuvant chemotherapy for overall survival, the consistent results and broad evidence base support adjuvant chemotherapy as the timing of choice[i, A].
34 What is the role of surgery for stage IIIA? n Stage Phase III Albain KS, et al INT T1 T3 N2 CDDP/VP16 x 2 + RT 45 Gy, thensurgery, and CDDP/VP16 x 2 CDDP/VP16 x 2 + RT 45 Gy, thenrt 16 Gy, thencddp/vp16 x 2 No statistical difference between both arms An unplanned exploratory analyses showed survival advantage for patients who underwent lobectomy Albain KS, et al. Lancet 2009
35 What is the role of surgery for stage IIIA? n Stage Phase III Van MeerbeeckJP, et al EORTC IIIA-N2 Cisplatin-based chemo. then surgery Cisplatin-based chemo. then RT 60 gy Unresectable disease at diagnosis Induction chemotherapy : ORR 61% 167 patients were allocated to resection and 165 to radiotherapy. Results : surgical resection did not improve overall survival compared with radiotherapy. Radiotherapy should be considered the preferred locoregional treatment for these patients. Van MeerbeeckJP, et al. J NatlCancer Inst2007
36 Neo adjuvant chemo. or neo adjuvant CT RT? n Stage Phase III SAKK 16/ Stage IIIA N2 Docetaxel/cisplatinx 3, thenradiotherapyfollowedby surgery Docetaxel/cisplatin x 3 then surgery Radiotherapy did not add any benefit to induction chemotherapy followed by surgery. Authors suggest that one definitive local treatment modality combined with neoadjuvant chemotherapy is adequate to treat resectable stage IIIA/N2 non-small-cell lung cancer. PlessM, et al. Lancet 2015
37 incidental IIIA(N2)(unforeseen N2) Recommendation: If, despite adequate mediastinal staging procedures, N2 disease is only documented intra-operatively, surgery should be followed by adjuvant chemotherapy [I, A]. In case of complete resection, addition of post-operative radiotherapy is not routinely recommended, but may be an option following individual risk assessment[v, C].
38 Potentially resectable IIIA(N2) disease(pre-operative diagnosis of IIIA-N2) several options: induction CT followed by surgery, induction CT/RT followed by surgery, or concurrent definitive CT/RT [I, A]. No recommendation can yet be made; however, an experienced multidisciplinary team is of paramount importance in any complex multi-modality treatment strategy decision. If induction chemotherapy alone is given preoperatively, postoperative radiotherapy is not standard treatment but may be an option based on critical evaluation of locoregional relapse risks[iv, C].
39 In potentially resectable superior sulcus tumours, concurrent chemoradiotherapy induction followed by definitive surgery is the treatment of choice [III, A]. The same strategy may be applied for potentially resectable T3 or T4 central tumours in highly selected cases and experienced centres[iii, B]. In both situations, surgery should be carriedoutwithin4weeksaftertheendofradiotherapy[iii,b].
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017
ESMO Preceptorship Programme NSCLC Singapore 15 November 2017 State of the art: Standard of care for resectable NSCLC Adjuvant chemotherapy Is there a place for neo-adjuvant chemotherapy? Pr Jaafar BENNOUNA
More informationAdjuvant Chemotherapy
State-of-the-art: standard of care for resectable NSCLC Adjuvant Chemotherapy JY DOUILLARD MD PhD Professor of Medical Oncology Integrated Centers of Oncology R Gauducheau University of Nantes France Adjuvant
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationIs the Neo-adjuvant Approach Better than Adjuvant Approach? Comparative Levels of Evidence: Randomized Trials
Is the Neo-adjuvant Approach Better than Approach? Virginie Westeel University Hospital Besançon, France Perspectives in Lung Cancer Amsterdam, 5-6 March 2010 Comparative Levels of Evidence: Randomized
More informationSystemic therapy in early stage NSCLC. Disclosures
Systemic therapy in early stage NSCLC Christian Manegold, MD Professor of Medicine, Heidelberg University Interdisciplinary Thoracic Oncology Department of Surgery University Medical Center Mannheim, Germany
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationDisclosures. Preoperative Treatment: Chemotherapy or ChemoRT? Adjuvant chemotherapy helps. so what about chemo first?
Disclosures Preoperative Treatment: Chemotherapy or ChemoRT? Advisory boards Genentech (travel only), Pfizer Salary support for clinical trials Celgene, Merck, Merrimack Matthew Gubens, MD, MS Assistant
More informationAdjuvant radiotherapy for completely resected early stage NSCLC
Adjuvant radiotherapy for completely resected early stage NSCLC ESMO Preceptorship on lung Cancer Manchester March 2018 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationAdjuvant Radiotherapy for completely resected NSCLC
Adjuvant Radiotherapy for completely resected NSCLC ESMO Preceptorship on lung Cancer Manchester February 2017 Cécile Le Péchoux Radiation Oncology Department IOT Institut d Oncologie Thoracique Local
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationAdjuvant Therapy in NSCLC. Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia
Adjuvant Therapy in NSCLC Dr.ssa Chiara Bennati Oncologia Medica S. Maria della Misericordia Perugia Agenda What do we expect today from new adjuvant chemotherapy Which data do we have with targeted agents
More informationAdjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer
Review Article Adjuvant chemotherapy in patients with completely resected nonsmall cell lung cancer Robert Pirker Department of Medicine I, Medical University of Vienna, Vienna, Austria Correspondence
More informationAdjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC)
Review Article Adjuvant chemotherapy of completely resected early stage nonsmall cell lung cancer (NSCLC) Ying Liang 1, Heather A. Wakelee 2 1 Department of Medical Oncology, Cancer Center, Sun Yat-sen
More informationNSCLC: Staging & Prognosis. Neoadjuvant chemotherapy. Controversies in the management of early NSCLC: neoadjuvant vs adjuvant chemotherapy
Controversies in the management of early NSCLC: neoadjuvant vs adjuvant Sarita Dubey sst Professor, Medical ncology, UCSF NSCLC: Staging & Prognosis Pathologic Survival elapse (%) Stage 5 yr (%) Local
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationTwo Cycles of Chemoradiation: 2 Cycles is Enough. Concurrent Chemotherapy / RT Regimens
1 Two Cycles of Chemoradiation: 2 Cycles is Enough Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Concurrent Chemotherapy / RT Regimens Cisplatin 50 mg/m 2 on days
More informationSystemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know)
Systemic therapy for Non-Small Cell Lung Cancer in 2013 (What you should know) นายแพทย ช ยย ทธ ย ทธ เจร ญธรรม หน วยมะเร งว ทยา ภาคว ชาอาย ร อาย รศาสตร Inter-hospitol Conference, 16 th March 2013 Systemic
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationHeather Wakelee, M.D.
Heather Wakelee, M.D. Assistant Professor of Medicine, Oncology Stanford University Sponsored by Educational Grant Support from Adjuvant (Post-Operative) Lung Cancer Chemotherapy Heather Wakelee, M.D.
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationMolly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010
LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical
More informationPrognostic and predictive biomarkers in
OLOGICAL SCIENCES O DEPT. OF CLINICAL & BIO UNIVERSITY UNIVERSTY OF TORINO Prognostic and predictive biomarkers in early stage NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical &
More informationENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias. Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA
ENFERMEDAD LOCALMENTE AVANZADA: Estado del Arte y Eventual Papel de las Nuevas Terapias Dolores Isla H. Clínico Universitario Lozano Blesa ZARAGOZA Formigal, 28 de Junio de 2018 CÓMO DEFINÍAMOS EL ESTADIO
More informationCombined modality treatment for N2 disease
Combined modality treatment for N2 disease Dr Clara Chan Consultant in Clinical Oncology 3 rd March 2017 Overview Background The evidence base Systemic treatment Radiotherapy Future directions/clinical
More informationOptimal Application of Adjuvant Therapy in NSCLC
Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial Stage n Chemo
More informationHeterogeneity of N2 disease
Locally Advanced NSCLC Surgery? No. Ramaswamy Govindan M.D Co-Director, Section of Medical Oncology Alvin J Siteman Cancer Center at Washington University School of Medicine St. Louis, Missouri Heterogeneity
More informationLA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II
AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco
More informationDebate on stage III NSCLC: The role of systemic therapy
1 Debate on stage III NSCLC: The role of systemic therapy Rolf Stahel University Hospital of Zürich Bucharest, 16.6..2015 2 Stage III disease: The problem of heterogeneity, the risk of distant metastases
More informationSlide 1. Slide 2 Post 1995 Meta-Analysis : Slide 3
Slide 1 Optimal Application of Adjuvant Therapy in NSCLC Heather Wakelee, MD Stanford University, Stanford Cancer Institute Slide 2 Post 1995 Meta-Analysis : NSCLC Randomized Adjuvant Platinum Trials Trial
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationThe 5-year survival in patients with resected NSCLC ranges
SHIRISH M. GADGEEL Role of Chemotherapy and Targeted Therapy in Early-Stage Non Small Cell Lung Cancer Shirish M. Gadgeel, MD OVERVIEW On the basis of several randomized trials and meta-analyses, adjuvant
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationNeo-adjuvant chemotherapy in NSCLC
SCLC Epidemiology eo-adjuvant chemotherapy in SCLC Sarita Dubey sst Professor, Medical ncology, UCSF UCSF/UC Davis Thoracic conference ovember 8, 2008 Statistics for 2008 Cancer Incidence Deaths Colon
More informationChemo-radiotherapy in non-small cell lung cancer. HARMESH R NAIK, MD. September 25, 2002
Chemo-radiotherapy in non-small cell lung cancer HARMESH R NAIK, MD. September 25, 2002 Epidemiology Estimated 170000 new cases Estimated 157,000 deaths Second commonest cancer diagnosis in men and women
More informationAdjuvant Chemotherapy for Non-small Cell Lung Cancer
PISA SYMPOSIUM Adjuvant Chemotherapy for Non-small Cell Lung Cancer Emilio Bria, MD, Federica Cuppone, MD, Fabiana Letizia Cecere, MD, Michele Milella, MD, Cecilia Nisticò, MD, Francesco Cognetti, MD,
More informationRuolo emergente dell immunoterapia nello stadio III. Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy)
Ruolo emergente dell immunoterapia nello stadio III Giulia Pasello Medical Oncology 2 Veneto Cancer Institute, Padua (Italy) Disclosures Advisory Boards / Honoraria / Speakers fee / Consultant for: MSD,
More informationThe Evolving Role of Adjuvant Therapies
Therapy-predictive markers for adjuvant chemotherapy The Evolving Role of Adjuvant Therapies Micrometastasis Prognostic Markers (BRCA1) Cured No Further Tx Chemosensitive Rafael Rosell th European Perspectives
More informationLung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We
Lung Cancer Non-small Cell Local, Regional, Small Cell, Other Thoracic Cancers: The Question Isn t Can We, but Should We Edward Garon, MD, MS Associate Professor Director- Thoracic Oncology Program David
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationERCC-1 1 and response to chemotherapy. Jean-Charles SORIA, MD, PhD Institut Gustave Roussy
ERCC-1 1 and response to chemotherapy 1 Jean-Charles SORIA, MD, PhD Institut Gustave Roussy Cancer and Chemotherapy: the exemple of Lung Cancer 2 50 CT + supportive care 40 Surgery ± CT Patients (%) 30
More informationGastroesophag Gastroesopha eal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. G. H addock Haddock M.D.
Gastroesophageal Junction Adenocarcinoma: What is the best adjuvant regimen? Michael G. Haddock M.D. Mayo Clinic Rochester, MN Locally Advanced GE Junction ACA CT S CT or CT S CT/RT Proposition Chemoradiation
More informationCALGB Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer
CALGB 30610 Thoracic Radiotherapy for Limited Stage Small Cell Lung Cancer Jeffrey A. Bogart Department of Radiation Oncology Upstate Medical University Syracuse, NY Small Cell Lung Cancer Estimated 33,000
More informationNeoplasie del laringe Diagnosi e trattamento
Neoplasie del laringe Diagnosi e trattamento Venerdì 22 maggio 2015 Alessandria Trattamenti non chirurgici: Preservazione d organo, malattia localmente avanzata Marco C Merlano A.O. S.Croce e Carle, Ospedale
More informationCANCER TREATMENT REGIMENS
CANCER TREATMENT S Lung Cancer The selection, dosing, and administration of anticancer agents and the management of associated toxicities are complex. Drug dose modifications and schedule and initiation
More informationMultidisciplinary interactive session (MIS) pn2: The optimal treatment in Wilfried Ernst Erich Eberhardt
Multidisciplinary interactive session (MIS) pn2: The optimal treatment in 2012 Wilfried Ernst Erich Eberhardt Department of Medicine (Cancer Res.), University Hospital Essen, West German Cancer Centre,
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationStage III NSCLC: Overview
Locally Advanced NSCLC: New Concepts in Combined Modality Therapy NSCLC: Stage Distribution Randeep Sangha, MD Visiting Assistant Professor UC Davis Cancer Center Sacramento, CA Stage III NSCLC: Overview
More informationClinical Activity Lung Cancer. Andrea Camerini Ospedale Versilia
Clinical Activity Lung Cancer Andrea Camerini Ospedale Versilia The three main objectives in advanced NSCLC 1. In advanced/metastatic cancer, palliation is often the primary treatment goal 2. Potential
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationStage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99
Stage III Non-Small Cell Lung Cancer, Is There Any Progress? HARMESH R NAIK, MD. KARMANOS CANCER INSTITUTE 2/24/99 Introduction 1/3 of the total lung cancer cases few patients are cured with single modality
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationTratamiento Multidisciplinar del CNMP Localmente Avanzado. Luis Paz-Ares
Tratamiento Multidisciplinar del CNMP Localmente Avanzado Luis Paz-Ares Indice Definición & Estadios Estadio IIIA N2 Estadio IIIB (y N2 irresecables) Conclusiones Indice Definición & Estadios Estadio IIIA
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationLung cancer update 2007
Lung cancer update 2007 HARMESH R NAIK, MD. January 24, 2007 Epidemiology (world) Estimated 1.35 million new cases in world in 2002 Estimated 1.179 million deaths in world in 2002 Common cancer diagnosis
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationJ Clin Oncol 28: by American Society of Clinical Oncology INTRODUCTION
VOLUME 28 NUMBER 11 APRIL 10 2010 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the University of Texas M. D. Anderson Cancer Center, Houston, TX; Puget Sound Cancer Consortium, Swedish
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationLung cancer is the leading cause of cancer-related death in
ORIGINAL ARTICLE Use of Adjuvant Chemotherapy in Non-small Cell Lung Cancer in Routine Practice Christophe Massard, MD,* Pierre Tran Ba Loc, MD, Vincent Haddad, MS, Jean-Pierre Pignon, MD, Philippe Girard,
More informationLung cancer in the elderly. D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium
Lung cancer in the elderly D. Schrijvers, MD, PhD Ziekenhuisnetwerk Antwerpen(ZNA)-Middelheim Antwerp Belgium Incidence and mortality of all cancers and lung cancer in relation to age and gender (US) 120,000
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationEVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI
EVIDENCE BASED MANAGEMENT OF STAGE III NSCLC MILIND BALDI Overview Introduction Diagnostic work up Treatment Group 1 Group 2 Group 3 Stage III lung cancer Historically was defined as locoregionally advanced
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationLung cancer is the leading cause of cancer mortality in the
STATE OF THE ART: CONCISE REVIEW Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer Christopher M. Booth, MD, FRCPC, and Frances A. Shepherd, MD, FRCPC Abstract: Despite improved surgical techniques,
More informationThe Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy
The Role of Consolidation Therapy for Stage III Non-Small Cell Lung Cancer With Persistent N2 Disease After Induction Chemotherapy Arya Amini, BA, Arlene M. Correa, PhD, Ritsuko Komaki, MD, Joe Y. Chang,
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationAdjuvant therapy of NSCLC: where to go from here?
SAMO Winter Workshop on Chest Tumours Adjuvant therapy of NSCLC: where to go from here? J Vansteenkiste Dept Pulmonology Leuven Lung Cancer Group > adjuvant therapy ± 1,200,000 lung cancers worldwide >80%
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More information11/21/ M with LUL Mass Case Presentation / Round Table Discussion. Multiple-choice question What stage is this tumor?
MS 62M with LUL Mass Case Presentation / Round Table Discussion Dr. Jasleen Kukreja and Johannes Kratz Department of Thoracic Surgery University of California, San Francisco 62M, presented to clinic 6/2009
More informationAdjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine
Editorial Adjuvant EGFR TKI therapy for resectable non-small cell lung cancer: new era for personalized medicine Peng Shen 1, Wenzhao Zhong 2 1 Department of Oncology, Nanfang Hospital, Southern Medical
More informationCHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia.
! CHEMIOTERAPIA ADIUVANTE NEL NSCLC Dr. RITA CHIARI Oncologia Medica - Perugia ritachiar@gmail.com ! DICHIARAZIONE Relatore: RITA CHIARI Come da nuova regolamentazione della Commissione Nazionale per la
More informationCâncer de Pulmão Não Pequenas Células
Câncer de Pulmão Não Pequenas Células Carboplatina + Paclitaxel Paclitaxel: 200mg/m 2 IV D1 Carboplatina: AUC 6 IV D1 a cada 21 dias X 4 ciclos Ref. (1) Vinorelbina + Cisplatina Vinorelbina: 25mg/m 2 IV
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationIndividualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers
Review Individualized Adjuvant Chemotherapy for Surgically Resected Lung Cancer and the Roles of Biomarkers Norihiko Ikeda, MD, Seisuke Nagase, MD, and Tatsuo Ohira, MD Several prospective randomized trials
More informationThoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer
Thoracoscopic Lobectomy Is Associated With Superior Compliance With Adjuvant Chemotherapy in Lung Cancer Jin Gu Lee, MD, Byoung Chul Cho, MD, Mi Kyung Bae, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae
More informationCooperative Group Update - Japan; JCOG & WJOG -
Cooperative Group Update - Japan; JCOG & WJOG - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine, Yokohama City University Chief, Division of Thoracic Surgery, Respiratory Disease Center
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationNeodjuvant chemotherapy
Neodjuvant chemotherapy Dr Robert Huddart Senior Lecturer and Honorary Consultant in Clinical Oncology Royal Marsden Hospital and Institute of Cancer Research Why consider neo-adjuvant chemotherapy? Loco-regional
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationMetronomic chemotherapy for breast cancer
Metronomic chemotherapy for breast cancer M. Colleoni International Breast Cancer Study Group (IBCSG), Division of Medical Senology, European Institute of Oncology Metronomic Scheduling and Inhibition
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationThe road less travelled: what options are available for patients with advanced squamous cell carcinoma?
Robert Pirker Medical University of Vienna Vienna, Austria The road less travelled: what options are available for patients with advanced squamous cell carcinoma? Disclosures Honoraria for advisory board/consulting
More information